

Glenn T Stebbins

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1392021/publications.pdf>

Version: 2024-02-01

164
papers

17,312
citations

36691

53
h-index

17373

126
g-index

171
all docs

171
docs citations

171
times ranked

17331
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of motor, non-motor, and quality of life phenotype in Black and White patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2022, 96, 18-21.	1.1	4
2	Head tremor in cervical dystonia: Quantifying severity with computer vision. <i>Journal of the Neurological Sciences</i> , 2022, 434, 120154.	0.3	6
3	Validation of the Arabic Version of the Movement Disorder Society's Unified Parkinson's Disease Rating Scale. <i>Movement Disorders</i> , 2022, 37, 826-841.	2.2	2
4	Hold that pose: capturing cervical dystonia's head deviation severity from video. <i>Annals of Clinical and Translational Neurology</i> , 2022, 9, 684-694.	1.7	9
5	Validation of the Thai Version of the Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale. <i>Journal of Movement Disorders</i> , 2022, 15, 151-155.	0.7	4
6	Tracking Emergence of New Motor and Non-Motor Symptoms Using the MDS-UPDRS: A Novel Outcome Measure for Early Parkinson's Disease?. <i>Journal of Parkinson's Disease</i> , 2022, 12, 1345-1351.	1.5	6
7	Resolving Missing Data from the Movement Disorder Society Unified Parkinson's Disease Rating Scale: Implications for Telemedicine. <i>Movement Disorders</i> , 2022, 37, 1749-1755.	2.2	3
8	Dissecting the Domains of Parkinson's Disease: Insights from Longitudinal Item Response Theory Modeling. <i>Movement Disorders</i> , 2022, 37, 1904-1914.	2.2	4
9	Assessment of Ataxia Rating Scales and Cerebellar Functional Tests: Critique and Recommendations. <i>Movement Disorders</i> , 2021, 36, 283-297.	2.2	52
10	Toward eScales: Digital Administration of the International Parkinson and Movement Disorder Society Rating Scales. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 208-214.	0.8	5
11	Head tremor and pain in cervical dystonia. <i>Journal of Neurology</i> , 2021, 268, 1945-1950.	1.8	12
12	Does Raising the Arms Modify Head Tremor Severity in Cervical Dystonia?. <i>Tremor and Other Hyperkinetic Movements</i> , 2021, 11, 21.	1.1	3
13	Non-Motor Fluctuations in Parkinson's Disease: Validation of the Non-Motor Fluctuation Assessment Questionnaire. <i>Movement Disorders</i> , 2021, 36, 1392-1400.	2.2	16
14	Validation of the Polish version of the Unified Dyskinesia Rating Scale (UDysRS). <i>Neurologia i Neurochirurgia Polska</i> , 2021, 55, 186-194.	0.6	0
15	A Disease Progression Model to Quantify the Nonmotor Symptoms of Parkinson's Disease in Participants With Leucine-Rich Repeat Kinase 2 Mutation. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 508-518.	2.3	8
16	Validation of the Finnish Version of the Unified Dyskinesia Rating Scale. <i>European Neurology</i> , 2021, 84, 444-449.	0.6	0
17	Is Telemedicine the New Normal or Is the Office Visit Still the Movement Disorder Option of Choice?. <i>Movement Disorders</i> , 2021, 36, 1481-1482.	2.2	3
18	Prognostic Modeling of Parkinson's Disease Progression Using Early Longitudinal Patterns of Change. <i>Movement Disorders</i> , 2021, 36, 2853-2861.	2.2	7

#	ARTICLE	IF	CITATIONS
19	Novel approach to MDSâ€”UPDRS monitoring in clinical trials: Longitudinal Item Response Theory Models. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 1083-1091.	0.8	5
20	<scp>TikTok</scp> Tics: A Pandemic Within a Pandemic. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 1200-1205.	0.8	80
21	Rating scales for medication adherence in people living with Parkinson's disease. <i>JB Evidence Synthesis</i> , 2021, Publish Ahead of Print, .	0.6	1
22	Does <scp>MDSâ€”UPDRS</scp> Provide Greater Sensitivity to Mild Disease than <scp>UPDRS</scp> in De Novo Parkinson's Disease?. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 1092-1099.	0.8	4
23	In Support of Electronic Versions of <scp>Movement Disorder Society</scp> Rating Scales. <i>Movement Disorders</i> , 2021, 36, 270-271.	2.2	2
24	Reliability, feasibility and satisfaction of telemedicine evaluations for cervical dystonia. <i>Journal of Telemedicine and Telecare</i> , 2020, 26, 560-567.	1.4	11
25	The Cortical Basal ganglia Functional Scale (CBFS): Development and preliminary validation. <i>Parkinsonism and Related Disorders</i> , 2020, 79, 121-126.	1.1	11
26	The Parkinsonâ€™s Disease Comprehensive Response (PDCORE): a composite approach integrating three standard outcome measures. <i>Brain Communications</i> , 2020, 2, fcaa046.	1.5	8
27	Item Response Theory Analysis of the <scp>MDS</scp>â€”<scp>UPDRS</scp> Motor Examination: Tremor vs. Nontremor Items. <i>Movement Disorders</i> , 2020, 35, 1587-1595.	2.2	18
28	Validation of the Hebrew Version of the Unified Dyskinesia Rating Scale. <i>Neuroepidemiology</i> , 2020, 54, 356-362.	1.1	1
29	Measuring Medication Adherence in Parkinson's Disease: A Systematic Review of Contributing Components in Rating Scales. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 607-615.	0.8	8
30	Development and Validation of the Orthostatic Tremor Severity and Disability Scale (<scp>OT</scp>â€”10). <i>Movement Disorders</i> , 2020, 35, 1796-1801.	2.2	7
31	Outcome measurement in functional neurological disorder: a systematic review and recommendations. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 638-649.	0.9	77
32	Determinants of placebo effects. <i>International Review of Neurobiology</i> , 2020, 153, 27-47.	0.9	8
33	Placebo Response in Fragile Xâ€”associated Tremor/Ataxia Syndrome. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 298-302.	0.8	1
34	Relationship of Movement Disorders Societyâ€”Unified Parkinson's Disease Rating Scale Nonmotor Symptoms to Cognitive Functioning in Patients with Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 279-283.	0.8	4
35	The Progressive Supranuclear Palsy Clinical Deficits Scale. <i>Movement Disorders</i> , 2020, 35, 650-661.	2.2	31
36	Movement Disorder Societyâ€”Unified Parkinson's Disease Rating Scale Use in the Covidâ€”19 Era. <i>Movement Disorders</i> , 2020, 35, 911-911.	2.2	34

#	ARTICLE	IF	CITATIONS
37	It's tricky: Rating alleviating maneuvers in cervical dystonia. <i>Journal of the Neurological Sciences</i> , 2020, 419, 117205.	0.3	6
38	Postural Directionality and Head Tremor in Cervical Dystonia. <i>Tremor and Other Hyperkinetic Movements</i> , 2020, 10, .	1.1	10
39	Kinesthetic Cells within the Subthalamic Nucleus and Deep Brain Stimulation for Parkinson Disease. <i>World Neurosurgery</i> , 2020, 139, e784-e791.	0.7	2
40	Telemedicine vs Office Visits in a Movement Disorders Clinic: Comparative Satisfaction of Physicians and Patients. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 65-69.	0.8	40
41	The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2019, 9, 553-563.	1.5	29
42	Successful use of the Unified Dyskinesia Rating Scale regardless of PD- or dyskinesia-duration. <i>Parkinsonism and Related Disorders</i> , 2019, 67, 113-116.	1.1	0
43	Scales to assess impulsive and compulsive behaviors in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2019, 34, 791-798.	2.2	49
44	The Parkinson's disease e-diary: Developing a clinical and research tool for the digital age. <i>Movement Disorders</i> , 2019, 34, 676-681.	2.2	43
45	Clinimetric Properties of the Fragile X-associated Tremor Ataxia Syndrome Rating Scale. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 120-124.	0.8	12
46	Sensory Tricks Are Associated with Higher Sleep-Related Quality of Life in Cervical Dystonia. <i>Tremor and Other Hyperkinetic Movements</i> , 2019, 9, .	1.1	2
47	Reply: MoCA for cognitive screening in Parkinson's disease: Beware of floor effect. <i>Movement Disorders</i> , 2018, 33, 499-500.	2.2	2
48	Evolution of diagnostic criteria and assessments for Parkinson's disease mild cognitive impairment. <i>Movement Disorders</i> , 2018, 33, 503-510.	2.2	52
49	Rating Scales and Performance-based Measures for Assessment of Functional Ability in Huntington's Disease: Critique and Recommendations. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 361-372.	0.8	22
50	Quality of Life in Huntington's Disease: Critique and Recommendations for Measures Assessing Patient Health-Related Quality of Life and Caregiver Quality of Life. <i>Movement Disorders</i> , 2018, 33, 742-749.	2.2	23
51	Rating scales for cognition in Huntington's disease: Critique and recommendations. <i>Movement Disorders</i> , 2018, 33, 187-195.	2.2	38
52	Validation study of the hoehn and yahr scale included in the MDS-UPDRS. <i>Movement Disorders</i> , 2018, 33, 651-652.	2.2	32
53	Clinical Rating Scales for Urinary Symptoms in Parkinson Disease: Critique and Recommendations. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 479-491.	0.8	18
54	Relationship between the MDS-UPDRS and Quality of Life: A large multicenter study of 3206 patients. <i>Parkinsonism and Related Disorders</i> , 2018, 52, 83-89.	1.1	46

#	ARTICLE	IF	CITATIONS
55	Turkish Standardization of Movement Disorders Society Unified Parkinson's Disease Rating Scale and Unified Dyskinesia Rating Scale. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 54-59.	0.8	18
56	Global scales for cognitive screening in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2018, 33, 208-218.	2.2	138
57	Rating Scales for Motor Symptoms and Signs in Huntington's Disease: Critique and Recommendations. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 111-117.	0.8	27
58	White matter abnormalities in the corpus callosum with cognitive impairment in Parkinson disease. <i>Neurology</i> , 2018, 91, e2244-e2255.	1.5	66
59	Missing Data in the Unified Dyskinesia Rating Scale (UDysRS). <i>Movement Disorders Clinical Practice</i> , 2018, 5, 523-526.	0.8	3
60	Detecting Mild Cognitive Deficits in Parkinson's Disease: Comparison of Neuropsychological Tests. <i>Movement Disorders</i> , 2018, 33, 1750-1759.	2.2	42
61	Reply: Hoehn and Yahr stage 3 and Postural stability item in the Movement Disorder Society's Unified Parkinson's Disease Rating Scale. <i>Movement Disorders</i> , 2018, 33, 1189-1190.	2.2	0
62	What influences placebo and nocebo responses in Parkinson's disease?. <i>Movement Disorders</i> , 2018, 33, 1204-1212.	2.2	15
63	Cross-Cultural Differences of the Non-Motor Symptoms Studied by the Traditional Chinese Version of the International Parkinson and Movement Disorder Society's Unified Parkinson's Disease Rating Scale. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 68-77.	0.8	29
64	Systematic review of severity scales and screening instruments for tics: Critique and recommendations. <i>Movement Disorders</i> , 2017, 32, 467-473.	2.2	92
65	Corpus callosal atrophy and associations with cognitive impairment in Parkinson disease. <i>Neurology</i> , 2017, 88, 1265-1272.	1.5	71
66	Differences in MDS-UPDRS Scores Based on Hoehn and Yahr Stage and Disease Duration. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 536-544.	0.8	65
67	Response to letter by Saenz-Farret et al. on "Rating scales for behavioral symptoms in Huntington's disease: Critique and recommendations". <i>Movement Disorders</i> , 2017, 32, 482-482.	2.2	0
68	Differential item functioning in the Unified Dyskinesia Rating Scale (UDysRS). <i>Movement Disorders</i> , 2017, 32, 1244-1249.	2.2	5
69	Validation of the Hebrew version of the Movement Disorder Society's Unified Parkinson's Disease Rating Scale. <i>Parkinsonism and Related Disorders</i> , 2017, 45, 7-12.	1.1	9
70	Topiramate as an adjunct to amantadine in the treatment of dyskinesia in parkinson's disease: A randomized, double-blind, placebo-controlled multicenter study. <i>Movement Disorders</i> , 2017, 32, 1335-1336.	2.2	12
71	Rating scales for behavioral symptoms in Huntington's disease: Critique and recommendations. <i>Movement Disorders</i> , 2016, 31, 1466-1478.	2.2	44
72	Disability Rating Scales in Parkinson's Disease: Critique and Recommendations. <i>Movement Disorders</i> , 2016, 31, 1455-1465.	2.2	87

#	ARTICLE	IF	CITATIONS
73	Clinimetric testing of the comprehensive cervical dystonia rating scale. <i>Movement Disorders</i> , 2016, 31, 563-569.	2.2	36
74	Knowledge gaps and research recommendations for essential tremor. <i>Parkinsonism and Related Disorders</i> , 2016, 33, 27-35.	1.1	46
75	Clinimetric Analysis of the Motor Section of the Progressive Supranuclear Palsy Rating Scale: Reliability and Factor Analysis. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 65-67.	0.8	6
76	Failing as doorman and disc jockey at the same time: Amygdalar dysfunction in Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 11-22.	2.2	31
77	Association of <i>GBA</i> Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease. <i>JAMA Neurology</i> , 2016, 73, 1217.	4.5	185
78	Gender-, age-, and race/ethnicity-based differential item functioning analysis of the movement disorder society-sponsored revision of the Unified Parkinson's disease rating scale. <i>Movement Disorders</i> , 2016, 31, 1865-1873.	2.2	4
79	<i>GBA</i> Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 95-102.	2.2	158
80	Association of the Fractal Dimension of Retinal Arteries and Veins with Quantitative Brain MRI Measures in HIV-Infected and Uninfected Women. <i>PLoS ONE</i> , 2016, 11, e0154858.	1.1	11
81	Handling missing values in the MDS-UPDRS. <i>Movement Disorders</i> , 2015, 30, 1632-1638.	2.2	33
82	Diagnosing PD-MCI by MDS task force criteria: How many and which neuropsychological tests?. <i>Movement Disorders</i> , 2015, 30, 402-406.	2.2	125
83	Development and validation of a clinical scale for rating the severity of Blepharospasm. <i>Movement Disorders</i> , 2015, 30, 525-530.	2.2	60
84	Cognitive profile of <i>LRRK2</i> -related Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 728-733.	2.2	64
85	Development of the Comprehensive Cervical Dystonia Rating Scale: Methodology. <i>Movement Disorders Clinical Practice</i> , 2015, 2, 135-141.	0.8	47
86	Using Cognitive Pretesting in Scale Development for Parkinson's Disease: The Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Example. <i>Journal of Parkinson's Disease</i> , 2014, 4, 395-404.	1.5	12
87	Official Japanese Version of the International Parkinson and Movement Disorder Society's Unified Parkinson's Disease Rating Scale: Validation Against the Original English Version. <i>Movement Disorders Clinical Practice</i> , 2014, 1, 200-212.	0.8	47
88	Independent Spanish Validation of the Unified Dyskinesia Rating Scale. <i>Movement Disorders Clinical Practice</i> , 2014, 1, 213-218.	0.8	6
89	Visuoperceptive region atrophy independent of cognitive status in patients with Parkinson's disease with hallucinations. <i>Brain</i> , 2014, 137, 849-859.	3.7	135
90	Beyond a motor disorder: A prospective evaluation of sleep quality in cervical dystonia. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 405-408.	1.1	49

#	ARTICLE	IF	CITATIONS
91	The tools of the trade: A state of the art "How to Assess Cognition" in the patient with Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 584-596.	2.2	52
92	Relationships among cognitive impairment, sleep, and fatigue in Parkinson's disease using the MDS-UPDRS. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1135-1139.	1.1	38
93	<scp>IPMDS</scp> "Sponsored Scale Translation Program: Process, Format, and Clinimetric Testing Plan for the <scp>MDS</scp>" "UPDRS" and UDysRS. <i>Movement Disorders Clinical Practice</i> , 2014, 1, 97-101.	0.8	30
94	I finally see what you see: Parkinson's disease visual hallucinations captured with functional neuroimaging. <i>Movement Disorders</i> , 2014, 29, 115-117.	2.2	55
95	Review of Quality of Life Instruments for the Restless Legs Syndrome/Willis-Ekbom Disease (RLS/WED): Critique and Recommendations. <i>Journal of Clinical Sleep Medicine</i> , 2014, 10, 1351-1357.	1.4	25
96	Review of Diagnostic Instruments for the Restless Legs Syndrome/Willis-Ekbom Disease (RLS/WED): Critique and Recommendations. <i>Journal of Clinical Sleep Medicine</i> , 2014, 10, 1343-1349.	1.4	47
97	Validation of the Italian version of the Movement Disorder Society "Unified Parkinson" Disease Rating Scale. <i>Neurological Sciences</i> , 2013, 34, 683-687.	0.9	123
98	Dystonia rating scales: Critique and recommendations. <i>Movement Disorders</i> , 2013, 28, 874-883.	2.2	150
99	Dissociations among daytime sleepiness, nighttime sleep, and cognitive status in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 806-811.	1.1	64
100	Defining optimal cutoff scores for cognitive impairment using Movement Disorder Society Task Force criteria for mild cognitive impairment in Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 1972-1979.	2.2	110
101	The MDS-UPDRS Part II (motor experiences of daily living) resulted useful for assessment of disability in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 889-893.	1.1	55
102	Task force report: Scales for screening and evaluating tremor: Critique and recommendations. <i>Movement Disorders</i> , 2013, 28, 1793-1800.	2.2	124
103	Expanded and independent validation of the Movement Disorder Society "Unified Parkinson" Disease Rating Scale (MDS-UPDRS). <i>Journal of Neurology</i> , 2013, 260, 228-236.	1.8	169
104	How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson's disease rating scale: Comparison with the unified Parkinson's disease rating scale. <i>Movement Disorders</i> , 2013, 28, 668-670.	2.2	622
105	Which dyskinesia scale best detects treatment response?. <i>Movement Disorders</i> , 2013, 28, 341-346.	2.2	76
106	Vibration Therapy for Parkinson's Disease: Charcot's Studies Revisited. <i>Journal of Parkinson's Disease</i> , 2012, 2, 23-27.	1.5	15
107	Atrophy and dysfunction of parahippocampal white matter in mild Alzheimer's disease. <i>Neurobiology of Aging</i> , 2012, 33, 43-52.	1.5	28
108	Age-related changes in the mesial temporal lobe: the parahippocampal white matter region. <i>Neurobiology of Aging</i> , 2012, 33, 1168-1176.	1.5	21

#	ARTICLE	IF	CITATIONS
109	Calibration of unified Parkinson's disease rating scale scores to Movement Disorder Society's unified Parkinson's disease rating scale scores. <i>Movement Disorders</i> , 2012, 27, 1239-1242.	2.2	148
110	Intraoperative x-ray to measure distance between DBS leads: A reliability study. <i>Movement Disorders</i> , 2012, 27, 1056-1059.	2.2	7
111	Entorhinal cortex atrophy differentiates Parkinson's disease patients with and without dementia. <i>Movement Disorders</i> , 2012, 27, 727-734.	2.2	49
112	Clinical Rating Scale Development. , 2012, , 3-9.		8
113	Entorhinal cortex volume is associated with episodic memory related brain activation in normal aging and amnesic mild cognitive impairment. <i>Brain Imaging and Behavior</i> , 2011, 5, 126-136.	1.1	21
114	The Movement Disorders task force review of dysautonomia rating scales in Parkinson's disease with regard to symptoms of orthostatic hypotension. <i>Movement Disorders</i> , 2011, 26, 1985-1992.	2.2	52
115	Health-related quality of life scales in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2011, 26, 2371-2380.	2.2	234
116	Visual plus nonvisual hallucinations in Parkinson's disease: Development and evolution over 10 years. <i>Movement Disorders</i> , 2011, 26, 2196-2200.	2.2	79
117	Wearing off scales in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2011, 26, 2169-2175.	2.2	101
118	Temporal stability of the Unified Dyskinesia Rating Scale. <i>Movement Disorders</i> , 2011, 26, 2556-2559.	2.2	20
119	Task force report on scales to assess dyskinesia in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2010, 25, 1131-1142.	2.2	90
120	Teaching program for the movement disorder society's sponsored revision of the Unified Parkinson's Disease Rating Scale: (MDS-UPDRS). <i>Movement Disorders</i> , 2010, 25, 1190-1194.	2.2	48
121	Scales to assess sleep impairment in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2010, 25, 2704-2716.	2.2	214
122	A 12-Year Population-Based Study of Psychosis in Parkinson Disease. <i>Archives of Neurology</i> , 2010, 67, 996-1001.	4.9	323
123	Association Between Antipsychotics and Body Mass Index When Treating Patients with Tics. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2010, 20, 277-281.	0.7	17
124	Regional differences in relationships between apparent white matter integrity, cognition and mood in patients with ischemic stroke. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2010, 32, 673-681.	0.8	16
125	Effects of pioglitazone on diffusion tensor imaging indices in multiple sclerosis patients. <i>Neuroscience Letters</i> , 2010, 472, 153-156.	1.0	33
126	A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2009, 211, 124-130.	1.1	59

#	ARTICLE	IF	CITATIONS
127	Testing objective measures of motor impairment in early Parkinson's disease: Feasibility study of an at-home testing device. <i>Movement Disorders</i> , 2009, 24, 551-556.	2.2	130
128	Determinants of quality of life in children with Gilles de la Tourette syndrome. <i>Movement Disorders</i> , 2009, 24, 1070-1073.	2.2	86
129	Diffusion tensor imaging in Alzheimer's disease and mild cognitive impairment. <i>Behavioural Neurology</i> , 2009, 21, 39-49.	1.1	133
130	Gender Effects on HIV-Associated White Matter Alterations: A Voxel-Wise DTI Study. <i>Brain Imaging and Behavior</i> , 2008, 2, 177-191.	1.1	8
131	Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. <i>Movement Disorders</i> , 2008, 23, 2129-2170.	2.2	4,796
132	The Unified Dyskinesia Rating Scale: Presentation and clinimetric profile. <i>Movement Disorders</i> , 2008, 23, 2398-2403.	2.2	196
133	Gray Matter Atrophy in Patients With Ischemic Stroke With Cognitive Impairment. <i>Stroke</i> , 2008, 39, 785-793.	1.0	135
134	fMRI Activation Changes during Successful Episodic Memory Encoding and Recognition in Amnesic Mild Cognitive Impairment Relative to Cognitively Healthy Older Adults. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 26, 123-137.	0.7	67
135	White Matter Anisotropy and Depression Symptoms in Patients with HIV. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2008, 20, 458-465.	0.9	10
136	Predicting Functional Gains in a Stroke Trial. <i>Stroke</i> , 2007, 38, 2108-2114.	1.0	112
137	HIV-Associated Alterations in Normal-Appearing White Matter. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 46, 564-573.	0.9	77
138	Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. <i>Movement Disorders</i> , 2007, 22, 41-47.	2.2	1,097
139	Depression rating scales in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2007, 22, 1077-1092.	2.2	583
140	White matter changes in mild cognitive impairment and AD: A diffusion tensor imaging study. <i>Neurobiology of Aging</i> , 2006, 27, 663-672.	1.5	423
141	Longitudinal changes in white matter following ischemic stroke: A three-year follow-up study. <i>Neurobiology of Aging</i> , 2006, 27, 1827-1833.	1.5	59
142	The Malignant Course of "Benign Hallucinations" in Parkinson Disease. <i>Archives of Neurology</i> , 2006, 63, 713.	4.9	147
143	Hippocampal disconnection contributes to memory dysfunction in individuals at risk for Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 10041-10045.	3.3	167
144	Not Just Another Pretty Picture. <i>Journal of the International Neuropsychological Society</i> , 2005, 11, 340-341.	1.2	0

#	ARTICLE	IF	CITATIONS
145	MovementDisorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations TheMovementDisorder Society Task Force on rating scales for Parkinson's disease. Movement Disorders, 2004, 19, 1020-1028.	2.2	1,739
146	Assuring interrater reliability for the UPDRS motor section: Utility of the UPDRS teaching tape. Movement Disorders, 2004, 19, 1453-1456.	2.2	73
147	Rating scales for dystonia: A multicenter assessment. Movement Disorders, 2003, 18, 303-312.	2.2	328
148	Aging effects on memory encoding in the frontal lobes.. Psychology and Aging, 2002, 17, 44-55.	1.4	188
149	Aging effects on memory encoding in the frontal lobes. Psychology and Aging, 2002, 17, 44-55.	1.4	91
150	Impaired Frontostriatal Cognitive Functioning Following Posteroventral Pallidotomy in Advanced Parkinson's Disease. Brain and Cognition, 2000, 42, 348-363.	0.8	53
151	Delayed recognition memory in Parkinsons disease: a role for working memory?. Neuropsychologia, 1999, 37, 503-510.	0.7	54
152	The effect of changes in head posture on the patterns of muscle activity in cervical dystonia (CD). Movement Disorders, 1998, 13, 490-496.	2.2	11
153	Neuropsychological Dissociation Between Recognition Familiarity and Perceptual Priming in Visual Long-Term Memory. Cortex, 1998, 34, 493-511.	1.1	55
154	PSYCHOTIC SYMPTOMS IN PARKINSON'S DISEASE. Journal of the American Geriatrics Society, 1997, 45, 252-252.	1.3	6
155	The stability of carbidopa in solution. Movement Disorders, 1997, 12, 608-610.	2.2	4
156	Efficacy of a patient-training videotape on motor fluctuations for on-off diaries in parkinson's disease. Movement Disorders, 1997, 12, 1039-1041.	2.2	51
157	Reduced working memory span in Parkinson's disease: Evidence for the role of frontostriatal system in working and strategic memory.. Neuropsychology, 1996, 10, 322-332.	1.0	213
158	Association of memory and cognition in Alzheimer's disease with volumetric estimates of temporal lobe structures.. Neuropsychology, 1996, 10, 459-463.	1.0	50
159	Selective impairments of memory functioning in unmedicated adults with Gilles de la Tourette's syndrome.. Neuropsychology, 1995, 9, 329-337.	1.0	33
160	Determining a Dose-Effect Curve for Botulinum Toxin in the Sternocleidomastoid Muscle in Cervical Dystonia. Clinical Neuropharmacology, 1994, 17, 188-195.	0.2	13
161	Quantitative Electromyographic Analysis of Changes in Muscle Activity Following Botulinum Toxin Therapy for Cervical Dystonia. Clinical Neuropharmacology, 1993, 16, 205-210.	0.2	24
162	Chapter 68 United Parkinson Foundation Neurotransplantation Registry: multicenter US and Canadian data base, presurgical and 12 month follow-up. Progress in Brain Research, 1990, 82, 611-617.	0.9	14

#	ARTICLE	IF	CITATIONS
163	Cognitive Assessment in Alzheimer's Disease: Cross-Sectional and Longitudinal Perspectives. Canadian Journal of Neurological Sciences, 1986, 13, 420-423.	0.3	45
164	Plasma 5-HT , tryptophan/neutral amino acid ratio and dexamethasone suppression in depression. Psychiatry Research, 1984, 11, 185-192.	1.7	59